HighGravityDataSigned in · PRO
Guidance history, every release
Raised · a change from the previous releaseSame · restated unchanged— · not stated in that releaseEvery value links to its sentence in the filing
| Metric | Nov 6, 2024 FY25 Q2 | Feb 5, 2025 FY25 Q3 | May 8, 2025 FY25 Q4 | Aug 6, 2025 FY26 Q1 | Nov 5, 2025 FY26 Q2 | Feb 4, 2026 FY26 Q3 | May 7, 2026 FY26 Q4 | Aug 5, 2026 FY27 Q1 |
|---|---|---|---|---|---|---|---|---|
| For FY2027 | ||||||||
| Adjusted Earnings per Diluted Share | — | — | — | — | — | — | — | New“$44.20 to $45.00” |
| Adjusted Earnings per Diluted Share | — | — | — | — | — | — | New“$43.80 to $44.60” | — |
| Adjusted Earnings per Diluted Share forecasted growth | — | — | — | — | — | — | New“12% to 14%” | — |
| For FY2026 | ||||||||
| Adjusted Earnings per Diluted Share | — | — | — | New“$37.10 to $37.90” | Raised“$38.35 to $38.85” | Raised“$38.80 to $39.20” | — | — |
| Adjusted Earnings per Diluted Share | — | — | New“$36.75 to $37.55” | — | — | — | — | — |
| Adjusted Earnings per Diluted Share accretion from anticipated held-for-sale accounting related to Norway sale | — | — | — | New“approximately $0.20” | — | — | — | — |
| Adjusted Earnings per Diluted Share forecasted growth | — | — | New“11% to 14%” | — | — | — | — | — |
| Adjusted Earnings per Diluted Share forecasted growth (excluding fiscal 2025 net gains associated with McKesson Ventures' equity investments) | — | — | New“13% to 16%” | — | — | — | — | — |
| Adjusted Earnings per Diluted Share growth vs prior year | — | — | — | New“12% to 15%” | — | — | — | — |
| Adjusted Earnings per Diluted Share growth vs. prior year | — | — | — | — | — | New“17% to 19%” | — | — |
| Adjusted EPS growth excluding fiscal 2025 net gains associated with McKesson Ventures' equity investments | — | — | — | New“14% to 17%” | — | — | — | — |
| Total authorized repurchases | — | — | — | — | — | — | New“$7.7 billion” | — |
| For FY2025 | ||||||||
| Adjusted Earnings per Diluted Share | New“$32.40 to $33.00” | Narrowed“$32.55 to $32.95” | — | — | — | — | — | — |
| Adjusted Earnings per Diluted Share growth vs. prior year | — | New“19% to 20%” | — | — | — | — | — | — |
| Adjusted Earnings per Diluted Share includes year-to-date gains from McKesson Ventures' equity investments | New“$0.53” | — | — | — | — | — | — | — |
| Share repurchases target | New“$3.2 billion” | — | — | — | — | — | — | — |
| No period stated | ||||||||
| Long-term Adjusted Earnings per Diluted Share growth target | — | — | New“12% to 14%” | — | — | — | Raised“13% to 16%” | — |
| Long-term Adjusted Segment Operating Profit growth target for North American Pharmaceutical | — | — | — | — | — | — | New“5% to 8%” | — |
| Long-term Adjusted Segment Operating Profit growth target for Oncology & Multispecialty | — | — | — | — | — | — | New“13% to 16%” | — |
| Long-term Adjusted Segment Operating Profit growth target for Prescription Technology Solutions | — | — | — | — | — | — | New“10% to 13%” | — |
| Long-term Adjusted Segment Operating Profit growth target for U.S. Pharmaceutical | — | — | New“6% to 8%” | — | — | — | — | — |
| Prescription Technology Solutions long-term Adjusted Segment Operating Profit growth target | — | — | New“11% to 12%” | — | — | — | — | — |
| Quarterly dividend | — | — | — | New“$0.82 per share” | — | — | — | Raised“$0.94 per share” |
| Share repurchase authorization increase | — | — | — | — | — | — | New“$5.0 billion” | — |
Values in quotation marks are the company’s words. Change labels compare each statement with the same metric and target year in the previous release. HighGravityData does not judge whether guidance was met.